3 results
Objectives Primary end point:- to define the MTD of IL-2, subcutaneously given once a day, 5 days per week, for 6 weeks, in combination with a fixed dose of sorafenib in patients with metastatic RCC, clear cell subtype. Secondary end points:- the…
To prospectively collect and assess global safety and efficacy data on the IN.PACT Admiral* Drug Eluting Balloon (DEB) in treatment of atherosclerotic disease of the superficial femoral and/or popliteal arteries in *real world* patient population.
Primary Objective: The primary objective of this study is to assess the efficacy of computer controlled cooling on postoperative pain in rest in the first 7 days of recovery, measured with the NRS score. Secondary Objectives: * Assess the effect of…